A5091283148- Virus-based gene therapy research
- Cancer Research and Treatments
- Monoclonal and Polyclonal Antibodies Research
- CAR-T cell therapy research
- ATP Synthase and ATPases Research
- Lung Cancer Treatments and Mutations
- Immunotherapy and Immune Responses
- Glioma Diagnosis and Treatment
- Angiogenesis and VEGF in Cancer
- Vascular Tumors and Angiosarcomas
- Immune Cell Function and Interaction
- Radiopharmaceutical Chemistry and Applications
- Cardiac tumors and thrombi
- T-cell and B-cell Immunology
- Toxin Mechanisms and Immunotoxins
- Vascular Malformations and Hemangiomas
- Bacteriophages and microbial interactions
- Neuroblastoma Research and Treatments
Spectrum Health
2024
Helen DeVos Children's Hospital
2024
Corewell Health Blodgett Hospital
2024
Indiana University – Purdue University Indianapolis
2019
Indiana University School of Medicine
2019
Riley Hospital for Children
2019
University of Minnesota
2017
University of Pittsburgh
2008
Sarcomas differ from carcinomas in their mesenchymal origin. Therapeutic advancements have come slowly, so alternative drugs and models are urgently needed. These studies report a new drug for sarcomas that simultaneously targets both tumor neovasculature. eBAT is bispecific angiotoxin consisting of truncated, deimmunized Pseudomonas exotoxin fused to EGF the amino terminal fragment urokinase. Here, we study an vivo "ontarget" companion dog trial as effectively kills canine hemangiosarcoma...
Abstract A subset of NK cells bears incomplete V(D)J rearrangements, but neither the consequence to cell activities nor precise developmental stages in which recombination occurs is known. These are important issues, as errors cause cancers B and T lineages. Using transgenic reporter mice examine dynamics vivo, we show that recombination+ have distinct patterns BM, including reduced homeostatic proliferation diminished Stat5 phosphorylation. In periphery, both recombination− mediate robust...
Children with high risk sarcoma have a poor prognosis despite surgical resection, irradiation and chemotherapy. Alternative therapies are urgently needed. Urokinase-type plasminogen activator receptor (uPAR) epidermal growth factor (EGFR) surface proteins expressed by some pediatric sarcomas. We show for the first time that de-immunized bispecific ligand toxin, EGFATFKDEL, directed against EGFR uPAR, successfully targets sarcoma. Using flow cytometry, we identified rhabdomyosarcoma (RMS)...
Hepatic angiosarcoma is an extremely rare diagnosis in children, with fewer than 50 pediatric cases reported the literature worldwide. This aggressive vascular sarcoma carries a very dismal prognosis and known to be resistant radiation, chemotherapy, other vascular-targeted agents. Complete surgical resection felt provide best chance for long-term survival. In patients tumors not amenable resection, liver transplant can considered. However, few such transplants have been reported, given that...
Abstract Background Ramucirumab is a monoclonal antibody that binds the extracellular domain of vascular endothelial growth factor receptor (VEGFR‐2) and prevents binding VEGF ligands. Based on population pharmacokinetic (PK) analysis correlation with efficacy in adults, target steady state trough concentration ( C ss,min ) ≥ 50 µg/mL was established. Procedures This phase 1 trial (ADVL1416) used rolling six design PK primary endpoint to define recommended 2 dose (RP2D) ramucirumab children...
<div>Abstract<p>Sarcomas differ from carcinomas in their mesenchymal origin. Therapeutic advancements have come slowly, so alternative drugs and models are urgently needed. These studies report a new drug for sarcomas that simultaneously targets both tumor neovasculature. eBAT is bispecific angiotoxin consisting of truncated, deimmunized <i>Pseudomonas</i> exotoxin fused to EGF the amino terminal fragment urokinase. Here, we study an <i>in vivo</i>...
<p>Detailed Methods for Immunohistochemistry Detailed Description of the Canine Clinical Study eBAT Pharmacokinetics and Neutralizing Antibody Assays Supplementary Table 1. Correlation between patient covariates death 2: Patient information (TMA) 3: Cox regression analysis time-to-progression Figure Survival probability based on EGFR 2. Quantification uPAR expression in normal canine tissues hemangiosarcoma 3. CONSORT diagram SRCBST study</p>
<p>Detailed Methods for Immunohistochemistry Detailed Description of the Canine Clinical Study eBAT Pharmacokinetics and Neutralizing Antibody Assays Supplementary Table 1. Correlation between patient covariates death 2: Patient information (TMA) 3: Cox regression analysis time-to-progression Figure Survival probability based on EGFR 2. Quantification uPAR expression in normal canine tissues hemangiosarcoma 3. CONSORT diagram SRCBST study</p>
<div>Abstract<p>Sarcomas differ from carcinomas in their mesenchymal origin. Therapeutic advancements have come slowly, so alternative drugs and models are urgently needed. These studies report a new drug for sarcomas that simultaneously targets both tumor neovasculature. eBAT is bispecific angiotoxin consisting of truncated, deimmunized <i>Pseudomonas</i> exotoxin fused to EGF the amino terminal fragment urokinase. Here, we study an <i>in vivo</i>...